Eugia Pharma gets USFDA nod for posaconazole injection, 300 mg/16.7 mL, single-dose vial
The approved product has an estimated market size of $25.4 million for the twelve months ending October 2023, according to IQVIA
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Graft-Versus-Host Disease
Markets for GvHD in five APAC markets to grow at 8.2 per cent CAGR in 10 years: GlobalData
The impact of approved therapies replacing generic off-label treatments will be the main driver of growth in the 5GM GvHD market
Global GVHD treatment market will thrive, reaching $545 million by 2023
The report also states that Roche’s Rituxan has emerged as the most clinically and commercially attractive therapy that is used in…